Table 1.
Baseline Characteristics of UCSF SCD Case-Control Study
| Characteristic | All SCD Cases (n= 107) | CAD Controls (n= 287) | P value* | Non-CAD Controls (n= 101) | P value* |
|---|---|---|---|---|---|
| Male (%)** | 92 (86.0%) | 243 (84.7%) | 0.75 | 90 (89.1%) | 0.50 |
| Ethnicity (%)** | 0.87 | 0.84 | |||
| White | 82 (76.6%) | 213 (74.2%) | 78 (77.2%) | ||
| Black | 5 (4.7%) | 21 (7.3%) | 7 (6.9%) | ||
| Asian | 11 (10.3%) | 33 (11.5%) | 10 (9.9%) | ||
| Hispanic | 6 (5.6%) | 14 (4.9%) | 5 (5.0%) | ||
| Other | 3 (2.8%) | 6 (2.1%) | 1 (1.0%) | ||
| Age at Index MI** | 57.1 ± 14.2 | 57.1 ± 12.4 | 0.96 | N/A | |
| Years of Follow Up since MI** | 14.4 ± 9.0 | 14.5 ± 8.9 | 0.93 | N/A | |
| Revascularization (%)** | |||||
| CABG | 56 (52.3%) | 142 (49.5%) | 0.61 | N/A | |
| Stent | 35 (32.7%) | 71 (24.7%) | 0.29 | N/A | |
| PTCA | 12 (11.2%) | 57 (19.9%) | 0.12 | N/A | |
| Diabetes (%) | 15 (18.1%) | 64 (22.4%) | 0.40 | 12 (12.2%) | 0.27 |
| Current Smoker (%) | 12 (14.6%) | 18 (6.3%) | 0.015 | 4 (4.1%) | 0.013 |
| BMI | 25.9 ± 4.6 | 26.9 ± 5.1 | 0.11 | 25.4 ± 3.3 | 0.50 |
| HTN (%) | 58 (54.2%) | 175 (61.0%) | 0.22 | 0 (0%) | 0.00 |
| Medications | |||||
| β blocker | 72 (67.3%) | 147 (51.2%) | 0.14 | N/A | |
| ACE-I/ARB | 55 (51.4%) | 105 (36.6%) | 0.057 | N/A | |
| Statin | 59 (55.1%) | 166 (57.8%) | 0.60 | N/A | |
| Aspirin | 74 (69.2%) | 201 (70.0%) | 0.95 | N/A |
*
from t-tests or chi-square tests for comparison with SCD cases
**
variables matched on a group level between SCD cases and CAD controls